[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@OncLive](/creator/twitter/OncLive) "Important data from the #MATTERHORN study shared by Dr @TaberneroJosep at #ESMO25 confirming an OS benefit in the FLOT + Durvalumab arm in the ITT population (HR XXXX XX% CI 0.63-0.96 p=0.021). Benefit enriched in PD-L1 TAP X% but also seen in X% group. Key finding that higher nodal clearance and pathologic response translates to EFS and OS in D+FLOT group. Major progress made since the MAGIC trial nearly XX years ago. @Jonathanwlee23 #CancerResearch #Oncology #MedTwitter" [X Link](https://x.com/OncLive/status/1979168743545581913) [@OncLive](/creator/x/OncLive) 2025-10-17T12:52Z 48.5K followers, XXX engagements "AbbVie Files BLA for First Hematologic ADC Pivekimab Sunirine In CADENZA pivekimab achieved a XX% cCR and XX% ORR in frontline BPDCN. Details here:" [X Link](https://x.com/OncLive/status/1980061399129673812) [@OncLive](/creator/x/OncLive) 2025-10-19T23:59Z 48.5K followers, XXX engagements "ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC @EmerikOsterlund @MDAndersonNews @myESMO #ESMO25" [X Link](https://x.com/OncLive/status/1982025589000159568) [@OncLive](/creator/x/OncLive) 2025-10-25T10:04Z 48.5K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@OncLive
"Important data from the #MATTERHORN study shared by Dr @TaberneroJosep at #ESMO25 confirming an OS benefit in the FLOT + Durvalumab arm in the ITT population (HR XXXX XX% CI 0.63-0.96 p=0.021). Benefit enriched in PD-L1 TAP X% but also seen in X% group. Key finding that higher nodal clearance and pathologic response translates to EFS and OS in D+FLOT group. Major progress made since the MAGIC trial nearly XX years ago. @Jonathanwlee23 #CancerResearch #Oncology #MedTwitter"
X Link @OncLive 2025-10-17T12:52Z 48.5K followers, XXX engagements
"AbbVie Files BLA for First Hematologic ADC Pivekimab Sunirine In CADENZA pivekimab achieved a XX% cCR and XX% ORR in frontline BPDCN. Details here:"
X Link @OncLive 2025-10-19T23:59Z 48.5K followers, XXX engagements
"ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC @EmerikOsterlund @MDAndersonNews @myESMO #ESMO25"
X Link @OncLive 2025-10-25T10:04Z 48.5K followers, XXX engagements
/creator/twitter::43051682/posts